- Home
- LCFY vs CNSP Comparison
LCFY vs CNSP Comparison
Compare LCFY & CNSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LCFY | CNSP |
|---|---|---|
| Founded | 2009 | 2017 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.3M | 8.5M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | LCFY | CNSP |
|---|---|---|
| Price | $2.42 | $5.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | ★ 6.4K | 3.7K |
| Earning Date | 05-12-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 8.03 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.10 | $1.90 |
| 52 Week High | $7.67 | $10.59 |
Technical Indicators
Market Signals| Indicator | LCFY | CNSP |
|---|---|---|
| Relative Strength Index (RSI) | 47.88 | 42.10 |
| Support Level | $2.18 | $4.64 |
| Resistance Level | $2.73 | $5.53 |
| Average True Range (ATR) | 0.17 | 0.13 |
| MACD | 0.03 | -0.07 |
| Stochastic Oscillator | 43.10 | 17.74 |
Price Performance
Historical ComparisonAbout LCFY Locafy Limited
Locafy Ltd is an Australian company currently focused on commercializing its Software as a Service (SaaS) online marketing technology (Technology), which prominently delivers a cost-effective location-based digital marketing solution for small businesses in the key markets of the USA, Australia and Canada. The company has two operating segments: Publishing and SEO Agency. The company derives the majority of its revenue from license subscription fees and advertising fees. Geographically, the maximum revenue is derived from North America.
About CNSP CNS Pharmaceuticals Inc.
CNS Pharmaceuticals Inc is a biotechnology company focused on developing therapies for serious diseases in neurology and oncology. The company is building a high-value pipeline for neurology and oncology indications. Its new corporate includes pivoting from a singular focus on glioblastoma multiforme and exploring out-licensing opportunities for its legacy assets, TPI 287 and Berubicin.